With its preference for glutamine and optimum activity at pH 6.0–7.0, the double-point mutant E380Q/S387L holds promise as a key component in a prospective glutenase formula for treating celiac disease, especially when combined with other peptidases possessing complementary properties, e.g., favoring proline at the P1 position and acting in more acidic conditions. Here, LAP3 is linked to celiac disease.